


Neuron Guard Revenue
Medical Equipment Manufacturing • Modena, Emilia-Romagna, Italy • 1-10 Employees
Neuron Guard revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $821,328 |
| Total funding | $635,300 |
Key Contact at Neuron Guard
Enrico Giuliani
CEO
Company overview
| Headquarters | Via Ludovico Castelvetro 19, Modena, Modena 41124, IT |
| Phone number | +3903521100366 |
| Website | |
| SIC | 384 |
| Founded | 2013 |
| Employees | 1-10 |
| Socials |
Neuron Guard Email Formats
Neuron Guard uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@neuronguard.com), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@neuronguard.com | 50% |
{first name}.{last name} | john.doe@neuronguard.com | 50% |
About Neuron Guard
Neuron Guard is an Italian medical device company that has developed a technology to deliver hot and cold therapy for body surfaces. One application is for selective brain temperature management. Other treatment options are focused on the need for local cooling or heating of body surfaces. The company was formally founded in 2013 for the development of portable non invasive cooling and warming systems. Our product CB240_Aurora is a portable hot or cold therapy system composed by a collar/wrap powered by a smart control unit. In 2022 CB240_Aurora has obtained the CE mark as a class II medical device under MDR, and is now sold in 5 countries in Europe (Italy, Finland, Sweden, Czech Republic and Austria). In 2023 Neuron Guard has obtained the ISO Certification 13485. We are committed to collaborating with relevant stakeholders to identify the needs and adapt our product to make it as usable and effective as possible and compliant with all relevant regulations. WHAT WE HAVE DONE SO FAR: • IP: 11 patents (Italy, Europe, USA, China, New Zealand, Canada, Australia, Israel, Brazil, Russia and Qatar), 3 patent pending applications • CLINICAL VALIDATION: A first-in-human pilot trial has successfully been completed at the Cambridge University Hospital Neurocritical Care Unit (Cambridge, UK), the largest Neurocritical Care Unit in Europe. The study demonstrated that CB240_Aurora is effective in achieving the clinical goal and being more brain selective than total body devices. The output of the trial has been published on Neurocritical Care (https://link.springer.com/article/10.1007/s12028-023-01800-7). • PRODUCTION: CB240_Aurora is produced in Italy. • COMMERCIALISATION: CB240_Aurora is currently sold through country distributors in Italy, Finland, Sweden, Czech Republic and Austria.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Neuron Guard has 1 employees across 1 departments.
Departments
Number of employees
Neuron Guard Tech Stack
Discover the technologies and tools that power Neuron Guard's digital infrastructure, from frameworks to analytics platforms.
Web servers
JavaScript libraries
Hosting
Photo galleries
Form builders
Programming languages
Font scripts
Blogs
Operating systems
Analytics
Maps
Databases
Frequently asked questions
4.8
40,000 users



